Search in the Abstract Database

Abstracts Search 2019

OP08 Long-term efficacy and pharmacodynamics of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn’s disease: the OPERA II study

G. D’Haens*1, W. Reinisch2, S. D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D. I. Park9, X. Hébuterne10, K. J. Gorelick11, S. W. Martin12, A. Banerjee12, P. Nagy13, Y. Wang14, F. Cataldi14, W. J. Sandborn15

1Academic Medical Centre, Amsterdam, The Netherlands, 2Medical University of Vienna, Vienna, Austria, 3University of Washington, Seattle, WA, USA, 4Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 5University Hospital of Liège, Liège, Belgium, 6Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 7University Hospital Ulm, Ulm, Germany, 8University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany, 9Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, 10University of Nice Sophia Antipolis, Hospital l’Archet, Nice, France, 11Zymo Consulting Group, Newtown Square, PA, USA, 12Pfizer, Cambridge, MA, USA, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, USA, 15University of California San Diego, La Jolla, CA, USA

Background

SHP647 is a fully human IgG2 anti-mucosal addressin cell adhesion molecule (MAdCAM-1) antibody in development for the treatment of Crohn’s disease (CD). OPERA II, a multi-centre, open-label, Phase 2 extension study (NCT01298492), aimed to assess the long-term safety and efficacy of SHP647 in moderate-to-severe CD.

Methods

Patients enrolled in OPERA II completed either 12 weeks’ induction treatment (placebo or SHP647 22.5, 75, or 225 mg sc) in OPERA (NCT01276509) regardless of response, or had a clinical response (≥3-point Harvey–Bradshaw Index [HBI] score decrease) to SHP647 225 mg in TOSCA (NCT01387594). In OPERA II, patients received SHP647 (75 mg sc) every 4 weeks from Week 0–72 and were followed up monthly for safety for a further 24 weeks. Dose reduction to 22.5 mg owing to intolerance/adverse events or escalation to 225 mg owing to clinical deterioration/poor response was allowed from Week 8 as judged by the investigator. High-sensitivity C-reactive protein (hsCRP), faecal calprotectin (FC), and HBI score were assessed as exploratory efficacy endpoints.

Results

Overall, 268 patients entered OPERA II and 149 completed; at baseline 169 patients from both OPERA and TOSCA were classed as responders (≥70-point decrease in Crohn’s Disease Activity Index in OPERA or ≥3-point decrease in HBI in TOSCA) and 89 from OPERA were non-responders. Remission rate (HBI <5) initially decreased in responders and increased in non-responders from baseline to Week 8; it was then maintained in both groups to Week 72 (Figure 1a). No patients de-escalated dose, but 157 patients escalated to 225 mg. Those who escalated had slightly higher hsCRP and FC concentrations at baseline than those who remained on 75 mg (mean [95% CI] hsCRP, 22.8 [18.6, 27.0] vs. 20.5 [15.9, 25.1] μg/ml; mean [95% CI] FC, 2662.7 [1977.9, 3347.5] vs. 1988.8 [1501.0, 2476.7] mg/kg). Concentrations of hsCRP and FC decreased from baseline to Week 72 in both groups, but remained higher in those who escalated; the decline in hsCRP and FC was slower in those who escalated (Figure 1b and c). Mean changes over time in remission rates (Figure 1d) were similar in both groups after an initial decrease in those who remained on 75 mg and an initial increase in those who escalated.

Abstract OP08 – Figure 1. Change over time in OPERA II in (a) mean remission rate (HBI score < 5) for responders and non-responders to treatment with SHP647 from OPERA (NCT01276509) and TOSCA (NCT01387594); (b) mean hsCRP concentrations (c) mean FC concentrations and (d) mean remission rate (HBI score < 5) over time in OPERA II for patients who dose-escalated to 225 mg vs. those who remained on 75 mg SHP647.

Conclusion

In this extension study, remission rates were sustained over 72 weeks with SHP647, regardless of initial response to induction treatment or dose-escalation status. hsCRP and FC levels were higher in patients who dose-escalated than those who remained on 75 mg. This adds to the evidence for long-term efficacy of SHP647.